deficiency syndrome (AIDS). 2, 8 After the advent of highly active antiretroviral therapy, the burden of all opportunistic infections related to AIDS patients, including cryptococcosis, decreased substantially. [9] [10] [11] [12] [13] On the other hand, solid organ transplant recipients persistently continue to be a major "at risk" population for cryptococcosis. For example, current experience indicates that 18%-65% of all cryptococcal diseases reported among HIV-negative patients occur in organ transplant recipients 7, 14, 15 and with an increasing worldwide transplant population, it is likely that cryptococcosis will continue to increase.
Cryptococcosis is specifically recognized as the second most common invasive fungal infection in renal transplant recipients in many countries, including Brazil, 16, 17 with incidence rates ranging from 0.3% to 5.5% and overall mortality rates as high as 20%-50% have been reported. [18] [19] [20] [21] [22] [23] Amphotericin B formulations are considered the best option for primary therapy and the 2010 IDSA Guidelines recommend lipid formulations of amphotericin B.
24-27
However, amphotericin B deoxycholate (AMBd) has been extensively used to treat cryptococcosis after renal transplantation in some cases related to acquisition costs 21, 24, [27] [28] [29] despite the fact that these patients face a high risk of nephrotoxicity and are frequently exposed to other nephrotoxic drugs such as calcineurin inhibitors.
Although AMBd-related nephrotoxicity in renal transplant recipients is expected, data regarding the impact of this therapeutic strategy are scarce in the medical literature in resource-limited medical communities. [29] [30] [31] [32] The North-American Guidelines for cryptococcosis suggest the use of lipid formulations of amphotericin B associated with flucytosine for induction therapy of central nervous system (CNS) and disseminated disease in solid organ transplant (SOT). 25 However, in most resource-limited countries, these 2 treatment options are either not available or too expensive. The purpose of this study was therefore to assess renal allograft dysfunction and its impact on renal transplant recipients with cryptococcosis receiving antifungal therapy in a single institution with standardized medical care system and without use of flucytosine and lipid formulations of amphotericin B.
| PATIENTS AND ME THODS

| Patients
The study consisted of a retrospective medical record review of all patients who developed cryptococcosis after renal transplantation 
| Definitions
An incident case was defined as a patient who developed cryptococcosis after renal transplantation based on the following diagnostic criteria 33, 34 
| Graft dysfunction
Renal allograft baseline outcomes were examined by analyzing the serum creatinine level at the time of the diagnosis of the cryptococcosis, first day of antifungal therapy, peak value during antifungal therapy and 15 days, 1, 2, 3, 6, 12, 18, 24, 36, and 48 months after the diagnosis of cryptococcal infection. Graft dysfunction was evaluated by comparing the serum creatinine level at the time of the cryptococcosis diagnosis (baseline creatinine) with the peak creatinine value observed during antifungal therapy and follow-up. Peak creatinine levels were defined as the maximum creatinine value during the study evaluation period. The intensity of dysfunction was also classified using 3 categories: (i) mild-the serum creatinine value increased up to 25% from baseline to peak; (ii) moderate-the increase was 26-50% from baseline to peak; and (iii) severe-the increase was greater than 50%. Graft loss was defined as the need for dialysis with or without graft removal.
| Mortality
The mortality rate was assessed at 30 and 90 days after the diagnosis of cryptococcosis and risk factors associated with this acute mortality were analyzed.
| Data collection
Epidemiological and clinical data in all cases of cryptococcal infection were collected from the medical records using a standard clinical report form. Variables assessed included demographic data, prior and concomitant infections, episodes of graft rejection, detailed transplant descriptions, immunosuppressive regimens and relevant laboratory data. In addition, we collected all data related to the antifungal therapeutic regimens employed, including the duration of therapy, total doses of AMBd, and concomitant use of other nephrotoxic agents.
| Statistical analysis
Continuous data were presented as either the mean ± SD or the median and range, and categorical data were presented as proportions. Univariate analyses were performed to compare categorical variables between the patients with and without graft loss using either the Chi-square or Fisher's exact test, as appropriate. The oneway ANOVA method was used to test differences between means.
The same analyses were used to evaluate factors associated with mortality. Graft survival rates were estimated using Kaplan-Meier methods, and comparisons between groups were performed using log-rank tests. All analyses were performed using SPSS software for
Windows, version 11.5 (SPSS, Chicago, IL). A value of P ≤ .05 was considered statistically significant.
| RE SULTS
| Baseline and clinical characteristics
During the 13-year study period, a total of 47 cases of cryptococcosis were identified among 5623 renal transplant recipients, representing an incidence rate of 8.4 per 1000 renal transplants in this health care system. The median follow-up period after cryptococcal diagnosis was a robust 18.8 months, ranging from 0 days to 11 years.
Of note, 36% of the patients died within 6 months after diagnosis of cryptococcosis and the follow-up was not available for 5 patients.
As indicated in This finding is consistent with the profile of donor types observed in our institution during the study period. Acute rejection episodes preceding fungal disease were documented in 18 (38.3%) patients, ranging from 37 days to 199 months before the onset of cryptococcal infection (average of 35 months). Patients with organ rejections were treated with high-dose steroid therapy (17 patients) and/or an antibody preparation (2 patients muromonab-CD3 and 2 thymoglobilin). Other baseline characteristics are outlined in Table 1 .
Cryptococcosis occurred >1 year after transplant in 76.6% of pa- 
| Allograft dysfunction
Creatinine values were available for 44 of 47 patients because 2 patients died before diagnosis and creatinine levels were missing for 1 patient who received fluconazole. The mean baseline serum creatinine value was 2.6 ± 1.66 mg/dL (range 0.6-7.6 mg/dL), and the mean peak creatinine level was 3.9 ± 2.17 mg/dL (range, 1.0-10.8 mg/ Univariate analysis consistently demonstrated that graft loss within 30 days after cryptococcosis was significantly associated with disseminated infections, greater baseline serum creatinine levels and graft dysfunction after AMBd treatment in the presence of additional nephrotoxic conditions (Table 2 ). Graft survival analysis
shows that the probability of graft survival after the diagnosis of cryptococcosis was significantly lower in patients treated with AMBd who had graft dysfunction in the presence of an additional nephrotoxic condition than in those without such a condition (P = .02, log rank test) (Figure 2 ). Of note, the amphotericin B duration and the modification of the immunosuppressive regimen, including suspension of a calcineurin inhibitor, were similar in both groups (Table 2) .
A multivariable analysis was not able to identify any independent risk factors associated with graft loss, and this finding was probably because of the limited number of patients.
We were not able to identify any correlation between a specific immunosuppressive regimen used in combination with amphotericin B and graft dysfunction. Indeed, graft dysfunction was even reported with patients receiving amphotericin B and rapamycin (a non-nephrotoxic immunosuppressive) at the time cryptococcosis was diagnosed. Finally, during the period of this study, only 3 patients (6.4%) met our criteria for immune reconstitution inflammatory syndrome (IRIS). The IRIS occurred after the graft dysfunction, and by timing did not appear to be associated with the allograft loss.
| Predictors of death
In our study, 9 of the 47 (19.2%) patients died within 30 days of being diagnosed with cryptococcosis, and 13 of 45 (28.9%) patients died within 90 days of diagnosis. The overall mortality rate in the study group was 48.9% (23/47) . Based on the univariate analysis, the following factors were significantly (P < .05) associated with high mortality at 30 days: disseminated and pulmonary infection, creatinine levels greater than 2.0 mg/dL at admission, somnolence at admission, high CSF opening pressure, positive CSF India ink, graft dysfunction in patients treated with AMBd with additional nephrotoxic conditions and graft loss within 30 days (Table 3) .
| D ISCUSS I ON
This study demonstrates important aspects of cryptococcosis in renal transplant recipients, treated with AMBd in a single public kidney transplant center in Brazil. Over the course of 13 years, 0.8% of renal transplant recipients developed cryptococcosis, and most F I G U R E 1 Temporal trend of serum creatinine levels in patients treated with amphotericin B according to the presence (n = 8) or absence of additional nephrotoxic conditions (n = 31) occurred a long time after transplantation. The incidence of cryptococcosis in renal transplant recipients observed in this study was similar to the low incidence rates reported by other groups (0.3%-5.5%), 16, 18, [20] [21] [22] [23] 32, [35] [36] [37] [38] [39] but with high mortality. 23 Among these 47 patients, the majority had received AMBd (87.2%) as first-line therapy.
Unfortunately, flucytosine or lipid formulation of amphotericin B
were not available or used during the study period, respectively. 
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The clinical impact of AMBd-nephrotoxicity appears to be amplified in patients exposed to other nephrotoxic conditions and in patients with preexisting renal dysfunctions before the initiation of AMBd treatment. [45] [46] [47] In this study, 95.5% of the cases developed renal graft dysfunction after beginning antifungal therapy for cryptococcosis. Furthermore, severe dysfunction was observed in 46.2% of these patients, and a substantial percentage (18.2%) of the patients in this study progressed to graft loss after the infection. For context, data recently provided by our institution describing a cohort of 10 400 kidney transplants reported 12.7% graft loss in deceasedrelated donor recipients after 1 year of transplant and 6.5% in livingrelated donor recipients within 1 year of transplant.
48
Although AMBd-related nephrotoxicity in renal transplant recipients is a crucial issue, it has been critically addressed in the medical literature. 31, 32 Conti et al showed that almost all renal transplant recipients (10 of 11) had graft loss after treatment with AMBd. 31 Also, in a retrospective study conducted by Wingard et al, 43 with serum creatinine levels higher than 2.5 mg/dL after starting AMBd, and 18% of these patients required hemodialysis but solid organ transplant recipients were less likely to die compared with bone marrow transplant patients. To limit graft damage by AMBd, some authors have suggested treating cryptococcosis with low doses of AMBd or repeated withdrawal of the antifungal drug when facing renal dysfunction. 29, 30 Of note, both strategies may negatively influence the patient outcome and the length of hospital stay. 49 Switching from AMBd to a less nephrotoxic antifungal agent after facing renal dysfunction may be a delayed strategy in the light of findings reported by Klibanov et al They found that only 5 of 25 patients who received AMBd and developed nephrotoxicity showed any improvement of their ongoing renal impairment after switching to an antifungal agent with less renal toxicity.
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Our data consistently showed that AMBd-treated cryptococcosis is associated with a high frequency of renal dysfunction and graft loss. In fact, graft loss was higher in patients exposed to AMBd with other nephrotoxic conditions. A recent study reviewed the literature of all cases of cryptococcosis in SOT recipients available in the PubMed database and found a significantly lower mortality rate among patients receiving lipid formulations of amphotericin B compared with those receiving AMBd and a higher mortality rate among patients with renal failure at baseline. 51 In another study of SOT recipients, patients treated with lipid formulations of amphotericin B had improved survival when compared with AMBd, even after controlling for factors such as renal failure at baseline and fungemia.
In this study the lipid formulation of amphotericin B-treated group mortality was 10.9% compare to 40% in the AMBd-treated group.
26
As noted in our study 90 day mortality reached almost 30%, it is likely that reduced nephrotoxicity in our patients could translate AMBd and with graft dysfunction were also found as predictors of mortality in our study. Probably, pulmonary involvement was a predictor of death because of the severe lung disease described secondary to late diagnosis (median of 102 days of pulmonary symptoms before diagnosis).
This study has certain limitations, including the fact that it is a retrospective study dealing with small numbers of pa- In summary, this study details allograft renal dysfunction after cryptococcosis in kidney transplant recipients. We found that graft dysfunction is common in patients treated for cryptococcosis and can drastically influence graft survival in this setting, especially in patients with conditions that clearly increase the risk of nephrotoxicity. It is extremely important in resource-limited health care systems that for this infection (meningitis/disseminated disease) every effort is made to use lipid formulations of amphotericin B for induction therapy or even consider the combination of flucytosine or fluconazole and make an effort to avoid AMBd. Finally, flucytosine should also be available for optimal combination induction therapy in health care systems that care for renal transplant recipients. In less-resourced health care systems the exceptions for successful management of cryptococcosis can be similar to resource-available systems and outcomes could be significantly improved by protecting renal functions.
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